Johnson & Johnson — TECVAYLI (teclistamab-cqyv) and DARZALEX FAS · Relapsed/refractory multiple myeloma (RRMM).
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (9/18/25) through T+5. Run-up high $248.56 on 3/2/26, low $174.16 on 9/25/25 (T-120 to T-1). FDA decision 3/5/26. Historical price action, not a forecast.
Key facts
FDA decision date2026-03-05
OutcomeApproved
Drug / candidateTECVAYLI (teclistamab-cqyv) and DARZALEX FAS